Methods of treating chronic kidney disease with dapagliflozin

MYPI2025007196A0Undetermined Publication Date: 2022-01-27ASTRAZENECA AB
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MYPI2025007196
Authority / Receiving Office
MY · MY
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-03-16
Filing Date
2021-04-01
Publication Date
2022-01-27
Patent Text Reader

Abstract

The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin. Figure 13.
Need to check novelty before this filing date? Find Prior Art